Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Taxane · 1 trial · 1 indication
Defined as time from date of randomisation until the date of objective radiological disease progression according to Blinded Independent Central Review (BICR) using RECIST 1.1 or death by any cause.
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Trastuzumab deruxtecan (T-DXd) plus pertuzumab-matching placebo |
| Arm B | EXPERIMENTAL | Trastuzumab deruxtecan (T-DXd) plus pertuzumab |
| Arm C | ACTIVE_COMPARATOR | Standard of care (Taxane (paclitaxel or docetaxel), trastuzumab, and pertuzumab) |
| Name | Type | Description |
|---|---|---|
| Trastuzumab deruxtecan | DRUG | Administered by intravenous infusion |
| Placebo | DRUG | Administered by intravenous infusion |
| Taxane | DRUG | Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion |
| Pertuzumab | DRUG | Administered by intravenous infusion |
| Trastuzumab | DRUG | Administered by intravenous infusion |
Key Inclusion Criteria: * Patients must be ≥18 years of age * Pathologically documented breast cancer that: 1. is advanced or metastatic 2. is locally assessed and prospectively centrally confirmed as HER2-positive (IHC3+ or ISH+) 3. is documented by local testing as hormone receptor (HR)-po...
Taxane is an investigational small molecule being studied in HER2-positive metastatic breast cancer. It is used as an active control in the DESTINY-Breast09 trial, where it is compared against trastuzumab deruxtecan with or without pertuzumab. The trial is in Phase 3 and is active but not recruiting.
Taxane is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is running a Phase 3 clinical trial of Taxane in HER2-positive metastatic breast cancer, with the drug serving as a comparator in the study.
Taxane is in Phase 3 clinical development. It is being evaluated in the DESTINY-Breast09 trial, which is active but not recruiting. The drug is investigational and has not been approved for any use.
Taxane is being studied in one Phase 3 trial, NCT04784715, titled "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)." The trial has enrolled 1,157 participants and is active but not recruiting.
No, Taxane is not the same as trastuzumab deruxtecan. In the DESTINY-Breast09 trial, Taxane is used as a control treatment, while trastuzumab deruxtecan is the experimental therapy being tested with or without pertuzumab. Taxane is a small molecule, whereas trastuzumab deruxtecan is an antibody-drug conjugate.